Publikation

The HeMoVal study protocol: a prospective international multicenter cohort study to validate cerebrospinal fluid hemoglobin as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury.

Wissenschaftlicher Artikel/Review - 18.07.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Akeret K, Buzzi R, Saxenhofer M, Bieri K, Chiavi D, Thomson B, Grüttner-Durmaz M, Schwendinger N, Humar R, Regli L, van Doormaal T, Held U, Keller E, Hugelshofer M, Schaer D, Hostettler I. The HeMoVal study protocol: a prospective international multicenter cohort study to validate cerebrospinal fluid hemoglobin as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury. BMC Neurol 2022; 22:267.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
BMC Neurol 2022; 22
Veröffentlichungsdatum
18.07.2022
eISSN (Online)
1471-2377
Seiten
267
Kurzbeschreibung/Zielsetzung

Preclinical studies provided a strong rationale for a pathophysiological link between cell-free hemoglobin in the cerebrospinal fluid (CSF-Hb) and secondary brain injury after subarachnoid hemorrhage (SAH-SBI). In a single-center prospective observational clinical study, external ventricular drain (EVD) based CSF-Hb proved to be a promising biomarker to monitor for SAH-SBI. The primary objective of the HeMoVal study is to prospectively validate the association between EVD based CSF-Hb and SAH-SBI during the first 14 days post-SAH. Secondary objectives include the assessment of the discrimination ability of EVD based CSF-Hb for SAH-SBI and the definition of a clinically relevant range of EVD based CSF-Hb toxicity. In addition, lumbar drain (LD) based CSF-Hb will be assessed for its association with and discrimination ability for SAH-SBI.